Oral anticholinergics in overactive bladder;Orale anticholinergika bei überaktiver blase

Urologe - Ausgabe A

Volumn 45, Issue 7, 2006, Pages 830-834

  Madersbacher, H ^a  

^a University Hospital LKH   (Austria)

Author keywords

CNS side effects; Muscarinic antagonists; Overactive bladder; Slow release formulations

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR THERAPY; BLOOD BRAIN BARRIER; CHOLINESTERASE INHIBITION; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; GERIATRIC PATIENT; HUMAN; LIPID SOLUBILITY; MEMORY DISORDER; NEUROGENIC BLADDER; NEUROTOXICITY; OVERACTIVE BLADDER; REVIEW; SLOW RELEASE FORMULATION; SYMPTOM;

ADMINISTRATION, ORAL; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COGNITION; COGNITION DISORDERS; HUMANS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33746256528     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1096-5     Document Type: Review

References (13)

1. Anderson KE (2002) Bladder activitation: afferent mechanisms. Urology 59(5 Suppl 1): 43-50
2. 2-Muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 275: 1654-1660
3. Chapple C, Khullar V, Zuhava G et al. (2005) The effects of Antimuscarinic Treatments in overactive bladder: A systematic review and meta-analysis. Eur Urol 48: 5-26
4. De Laet K, De Wachter S, Wyndaele JJ (2006) Systemic Oxybutynin decreases afferent activity of the pelvic nerve of the rat: New Insights into the working mechanism of antimuscarinics. J Neurourol Urodyn 25: 156-161
5. Gupka SK, Sathyan G 1999. Pharmacocinetics of an oral once-a-day controlled release oxybutynin formulation compared with immediate release oxybutynin. J Clin Pharmacol 39: 289-296
6. Herbison P, Hay-Smith J, Ellis G et al. (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: a systematic review. Br Med J 326: 841-848
7. 3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126: 810-825
8. Kay G, Crook T, Reheda L (2006) Effects of Darifenacin and extended release Oxybutynin on memory in older subjects. J Urol 175: 409
9. Lipton R, Kolodner K, Wesner K (2005) Assesment of cognitive function of the elderly population: effects of Darifenacin. J Urol 173: 493-498
10. Madersbacher H (2004) Confusion about measuring central nervous system effects. Curr Urol Rep 5: 442-446
11. Mattiasson A, Blaakaer J, Hoye K et al. (2003) Tolterodine. BJU Intern 91: 54-60
12. Thor KB, Katofiase MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Thera 274: 1014-1024
13. Yamanishi T, Sakakibara R, Uchiyama (2006) ICS 2005. Presented at the ICS 2005 meeting in Montreal, Quebec, Kanada